Stifel Nicolaus analyst Annabel Samimy has maintained their bullish stance on RGNX stock, giving a Buy rating on October 31.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Annabel Samimy has given her Buy rating due to a combination of factors that highlight RegenXBio’s strong position in the biotechnology sector. Despite recent uncertainties in the gene therapy space, particularly with the FDA’s decision on QURE’s program, RegenXBio’s rare disease initiatives are well-supported by robust clinical trials. These trials, such as RGX-121 for MPS-II and RGX-202 for DMD, are underpinned by pre-specified natural history comparators and long-term data, which bolster their credibility.
Furthermore, RegenXBio’s manufacturing capabilities are modernized and scalable, having passed FDA inspections without any issues, a rare achievement in the gene therapy field. The company also maintains a viable path for accelerated approval, contingent on high-quality clinical evidence and clear post-marketing commitments. These factors collectively reinforce the confidence in RegenXBio’s potential, justifying the Buy rating.
In another report released on October 31, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.